



FDA Approval for SonoSentry is Close

Melbourne, Australia – 23rd June 2014: Medical technology company iSonea Limited (ASX: ISN) is pleased to advise, that following a request for a Supervisory Review by the USA Food and Drug Administration (FDA) filed on March 14th 2014, iSonea will make labeling related changes for its SonoSentry device to obtain approval.

SonoSentry is designed to replace the legacy WheezeMeter product. SonoSentry is a portable acoustic device for measuring and recording WheezeRate. Whilst not smartphone enabled, the SonoSentry device uses a sensor head, iSonea's acoustic respiratory algorithms, and an LCD screen. The SonoSentry device provides iSonea with a product suitable for marketing in those markets, and market segments, where smartphone penetration, or use, is relatively low.

The SonoSentry was also submitted to provide insight into the FDA review process, which has proved to have been beneficial to the company, before filing an application for our AirSonea device.

The Chairman, Mr. Leon L'Huillier commented that "the new Board that assumed office in February 2014 is pleased with this outcome as FDA approval was one of its near term objectives outlined to shareholders in the Director's Report announced to ASX on 28th February 2014." The initial application for SonoSentry as an Over the Counter (OTC) device was first filed with the FDA in October 2012.

Contact:

Peter Vaughan
Company Secretary
+61 (0)3 9864 4825

Looking Forward Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on iSonea's current expectations, estimates and projections about the industry in which iSonea operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of iSonea, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. iSonea cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of iSonea only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. iSonea will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.